Package Leaflet: Information for the Patient
Zeffix 5mg/ml Oral Solution
lamivudine
Read all of this leaflet carefully before you start taking this medicine.
Contents of the pack
The active substance of Zeffix is lamivudine.
Zeffix is used to treat long-term (chronic) hepatitis B infection in adults.
Zeffix is an antiviral medicine that stops the hepatitis B virus from multiplying and belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
The hepatitis B virus infects the liver and can cause long-term (chronic) infection, which can lead to liver damage. Zeffix can be used in patients whose liver is damaged but still works normally (compensated liver disease) and in combination with other medicines in patients whose liver is damaged and does not work normally (decompensated liver disease).
Treatment with Zeffix can reduce the amount of hepatitis B virus in your body. This can lead to a reduction in liver damage and an improvement in the functioning of your liver. Not everyone responds to treatment with Zeffix in the same way. Your doctor will monitor the effectiveness of your treatment with regular blood tests.
Your doctor should offer you advice and testing for HIV infection before you start treatment with lamivudine for hepatitis B infection and during treatment. If you have or get HIV infection, see section 3.
Do not take Zeffix
Warnings and precautions
Some people who take Zeffix or similar medicines have a higher risk of serious side effects. You need to know that there is a higher risk:
Do not stop taking Zeffixwithout your doctor's advice, as there is a risk that your hepatitis may get worse. When you stop taking Zeffix, your doctor will monitor you for at least four months to check for any problems. This will involve taking blood samples to check for increases in liver enzyme levels that may indicate liver damage. See section 3 for more information on how to take Zeffix.
Protect others
Hepatitis B is spread by having sexual contact with someone who has the disease or by transferring infected blood (for example, by sharing needles). Zeffix does not prevent the risk of passing on hepatitis B infection to others. To prevent others from getting hepatitis B:
Other medicines and Zeffix
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those with herbal medicines or medicines without a prescription.
Remember to tell your doctor or pharmacist if you start taking any other medicine while you are taking Zeffix.
These medicines must not be taken with Zeffix:
Pregnancy
If you are pregnant, think you may be pregnant, or are planning to have a baby:
Do not stop taking Zeffix without your doctor's advice.
Breast-feeding
Zeffix can pass into breast milk. If you are breast-feeding or thinking of breast-feeding:
Driving and using machines
Zeffix can make you feel tired, which could affect your ability to drive or use machines.
Zeffix contains sugar, preservatives, propylene glycol, and sodium
If you are diabetic, note that each dose of Zeffix (100 mg – 20 ml) contains 4 g of sugar.
Zeffix contains sucrose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking Zeffix. Sucrose may be harmful to your teeth.
Zeffix contains preservatives (parahydroxybenzoates) that may cause allergic reactions (possibly delayed).
This medicine contains 400 mg of propylene glycol in each 20 ml.
This medicine contains 58.8 mg of sodium (a major component of table/cooking salt) in each 20 ml. This is equivalent to 2.9% of the maximum recommended daily intake of sodium for an adult.
Always take this medicine exactly as your doctor has told you.If you are not sure, check with your doctor or pharmacist.
Keep in regular contact with your doctor
Zeffix helps control your hepatitis B infection. You need to keep taking it every day to control the infection and prevent it from getting worse.
How much to take
The usual dose of Zeffix is 20ml(100 mg of lamivudine) once a day.
Your doctor may prescribe a lower dose if you have kidney problems.
Patients who also have or may get HIV infection
If you have or get HIV infection that is not being treated with medicines while you are taking lamivudine for hepatitis B infection, the HIV virus may become resistant to certain HIV medicines and become difficult to treat. Lamivudine is also used to treat HIV infection. Talk to your doctor if you have HIV infection. Your doctor may treat you with another medicine that contains a higher dose of lamivudine, usually 150 mg twice a day, as the lower dose of 100 mg is not enough to treat HIV infection. If you are planning to change your HIV treatment, discuss this change with your doctor before.
Swallow the tablet whole with water. Zeffix can be taken with or without food.
See the diagram and instructions for measuring and taking a dose of medicine after section 6 of this leaflet.
If you take more Zeffix than you should
If you accidentally take too much Zeffix, talk to your doctor or pharmacist, or go to the nearest hospital emergency department for advice. If possible, show them the Zeffix packaging.
If you forget to take Zeffix
If you miss a dose, take it as soon as you remember. Then continue taking it as before. Do not take a double dose to make up for missed doses.
Do not stop taking Zeffix
Do not stop taking Zeffix without talking to your doctor. There is a risk that your hepatitis may get worse (see section 2). When you stop taking Zeffix, your doctor will monitor you for at least four months to check for any problems. This means you will have blood tests to check for increases in liver enzyme levels that may indicate liver damage.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most common side effects reported with Zeffix in clinical trials were tiredness, respiratory tract infections, sore throat, headache, stomach discomfort and pain, nausea, vomiting, and diarrhea, increased liver enzymes, and increased muscle enzymes (see below).
Allergic reaction
This is rare (may affect up to 1 in 1,000 people). The signs include:
Side effects that are thought to be caused by Zeffix:
A very common side effect(may affect more than1 in 10people) that may appear in blood tests is
A common side effect(may affect up to 1 in 10people) is:
A common side effectthat may appear in blood tests is:
A very rare side effect(may affect up to 1 in 10,000 people) is:
Other side effects
Other side effects have been reported in a small number of people, but their exact frequency is unknown:
A side effect that may appear in blood tests is:
If you get side effects
Reporting side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not take this medicine after the expiry date which is stated on the packaging and bottle.
Do not store above 25°C.
Discard one month after first opening.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
What Zeffix contains
The active substance is lamivudine. Each ml of oral solution contains 5 mg of lamivudine.
The other ingredients are: sucrose, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), citric acid, propylene glycol (E1520), sodium citrate, artificial strawberry flavor, artificial banana flavor, purified water.
Appearance and packaging
Zeffix oral solution is available in packs containing a white polyethylene bottle with a child-resistant closure. The solution is clear, colorless, or pale yellow with a strawberry/banana flavor. The bottle contains 240 ml of lamivudine solution (5 mg/ml). The pack includes a graduated oral applicator in ml and an applicator adapter that must be fitted to the bottle before use.
Manufacturer | Marketing Authorization Holder |
GlaxoSmithKline Trading Services Limited 12 Riverwalk, Citywest Business Campus Dublin 24, Ireland D24 YK11 | GlaxoSmithKline Trading Services Limited 12 Riverwalk Citywest Business Campus Dublin 24, Ireland D24 YK11 |
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium GlaxoSmithKline Pharmaceuticals s.a./n.v. Tel: + 32 (0)10 85 52 00 | Lithuania GlaxoSmithKline Trading Services Limited Tel: + 370 80000334 |
Luxembourg GlaxoSmithKline Pharmaceuticals s.a./n.v. Belgium Tel: + 32 (0) 10 85 52 00 | |
Czech Republic GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 cz.info@gsk.com | Hungary GlaxoSmithKline Trading Services Limited Tel.: + 36 80088309 |
Denmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com | Malta GlaxoSmithKline Trading Services Limited Tel: + 356 80065004 |
Germany GlaxoSmithKline GmbH & Co. KG Tel.: + 49 (0)89 36044 8701 produkt.info@gsk.com | Netherlands GlaxoSmithKline BV Tel: + 31 (0) 33 2081100 |
Estonia GlaxoSmithKline Trading Services Limited Tel: + 372 8002640 | Norway GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Greece GlaxoSmithKline Μονοπρ?σωπη A.E.B.E. Tel: + 30 210 68 82 100 | Austria GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com |
Spain GlaxoSmithKline, S.A. Tel: + 34 900 202 700 es-ci@gsk.com | Poland GSK Services Sp.zo.o. Tel.: + 48 (0)22 576 9000 |
France Laboratoire GlaxoSmithKline Tél.: + 33 (0)1 39 17 84 44 diam@gsk.com | Portugal Glaxo Wellcome Farmacêutica, Lda. Tel: + 351 21 412 95 00 FI.PT@gsk.com |
Croatia GlaxoSmithKline Trading Services Limited Tel: + 385 800787089 | Romania GlaxoSmithKline Trading Services Limited Tel: + 40 800672524 |
Ireland GlaxoSmithKline Trading Services Limited Tel: + 353 (0)1 4955000 | Slovenia GlaxoSmithKline Trading Services Limited Tel: + 386 80688869 |
Iceland Vistor hf. Phone: + 354 535 7000 | Slovak Republic GlaxoSmithKline Trading Services Limited Tel: + 421 800500589 |
Italy GlaxoSmithKline S.p.A. Tel: + 39 (0)45 7741 111 | Finland GlaxoSmithKline Oy Phone/Tel: + 358 (0)10 30 30 30 |
Cyprus GlaxoSmithKline Trading Services Limited Tel: + 357 80070017 | Sweden GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com |
Latvia GlaxoSmithKline Trading Services Limited Tel: + 371 80205045 |
Date of last revision of this leaflet:05/2025
Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu
How to measure the dose and take the medication
To measure your dose accurately, use the oral applicator included in the packaging (see also Section 3).
When full, the applicator contains 10 ml of solution.
1 Remove the plastic wrapperfrom the applicator/adapter.
Discard the oral solution one month after it was first opened.